More Imagion Biosystems Ltd. news
Imagion Biosystems Ltd.ASX: IBX

Imagion Receive Positive FDA Feedback for HER2 Phase 2 Trial

Jul 9, 2025 at 11:53 PM EDT · Issued by Imagion Biosystems Ltd.

Filed with ASX · Jul 9, 2025 at 11:53 PM EDT

On 6ix: 6ix.com/news/imagion-receive-positive-fda-feedback-for-her2-phase-2-trial

Imagion Biosystems Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Imagion Biosystems Ltd. on 6ix

Earlier from Imagion Biosystems

  • Appendix 4C and Quarterly Activities Report - March 2025Apr 30, 2025
  • Appendix 4E and 2024 Financial ReportFeb 28, 2025
  • Imagion Initiates Manufacturing of Drug for Phase 2 StudyFeb 18, 2025
  • Quarterly Activities/Appendix 4C Cash Flow ReportJan 29, 2025
  • Successful Placement of A$3MOct 10, 2024

Later from Imagion Biosystems

  • Imagion MagSense Breast Cancer Program Phase 2 Trial UpdateJul 14, 2025
  • Appendix 4C and Quarterly Activities Report - June 2025Jul 28, 2025
  • Trading HaltJul 30, 2025
  • IBX Secures Firm Commitments for A$3.5m Capital RaisingAug 3, 2025
  • Appendix 4D and Half-yearly Financial ReportAug 27, 2025
All Imagion Biosystems news releases↗

Follow Imagion Biosystems into a list and get an email when it puts out news.

Follow Imagion Biosystems
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer